SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is a battleground after mixed earnings revealing robust subscriber and revenue growth collided with declining gross margins and escalating legal challenges concerning its compounded GLP-1s, intensifying a tug-of-war between bulls and bears amid high short interest.

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Vir Biotechnology Inc

Vir Biotechnology is trending due to a major strategic collaboration with Astellas to advance its PSMA-targeted PRO-XTEN T-cell engager, VIR-5500, bolstered by encouraging updated Phase 1 data demonstrating anti-tumor activity and a favorable safety profile in prostate cancer. This substantial deal is fueling community excitement and discussions about its potential to drive a short squeeze and re-rate the stock, though some investors remain cautious about historical volatility.

BlackRock Institutional Trust Company N.A. - iShares Expanded Tech-Software Sector ETF

iShares Expanded Tech-Software Sector ETF

The iShares Expanded Tech-Software Sector ETF (IGV) is seeing intense discussion and a significant sell-off as fears escalate that AI, particularly Anthropic's Claude, will fundamentally disrupt and devalue established software businesses; however, a vocal part of the community dismisses this as exaggerated market manipulation and an irrational overreaction.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is trending due to a significant stock drop, fueled by fears that Anthropic's Claude Code could disrupt its COBOL modernization and legacy consulting services. The community is debating if this is an overreaction or a legitimate AI-driven threat to Big Blue's established business model, despite IBM's existing AI initiatives and partnerships.

WeRide, Inc. operates as an investment holding company. It engages in the sale of autonomous driving vehicles, primarily including robobuses, robotaxis, robosweepers and related sensor suites. The company was founded by Tony Xu Han and Yan Li in February 2017 and is headquartered in Guangzhou, China.

WeRide Inc. - ADR

WeRide Inc. is trending following its robust Q3 earnings, showcasing a staggering 761% year-over-year robotaxi revenue growth and improved gross margins, fueling confidence in its path to profitability. The immediate catalysts include the launch of fully driverless commercial robotaxi services with Uber in Abu Dhabi and the award-winning performance of its WePilot ADAS system gaining OEM traction, even as the community expresses frustration over the stock's valuation disconnect despite significant institutional interest from ARK Invest.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

Kratos is seeing strong conversation after a solid Q4 earnings report, a new GE Aerospace engine contract for combat drones, and its selection for the $1.1 billion Drone Dominance Program. The community is largely bullish on the company's expansive pipeline in autonomous and hypersonic defense systems, viewing it as a pivotal player in the evolving global security landscape.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is trending as its upcoming Q4 earnings report is seen as a critical 'make-or-break' moment for validating its long-term 1,000+ qubit roadmap and commercial strategy. The community remains sharply divided between those optimistic about its strategic initiatives and those concerned with current valuation, R&D execution, and insider selling within the highly speculative quantum sector.

McDonald's Corp. engages in the operation and franchising of restaurants. It operates through the following segments: U.S., International Operated Markets, and International Developmental Licensed Markets and Corporate. The U.S. segment focuses its operations on the United States. The International Operated Markets segment consists of operations and the franchising of restaurants in Australia, Canada, France, Germany, Italy, the Netherlands, Russia, Spain, and the U.K. The International Developmental Licensed Markets and Corporate segment consists of developmental licensee and affiliate markets in the McDonald’s system. The firm's products include Big Mac, Quarter Pounder with Cheese, Filet-O-Fish, several chicken sandwiches, Chicken McNuggets, wraps, McDonald's Fries, salads, oatmeal, shakes, McFlurry desserts, sundaes, soft serve cones, pies, soft drinks, coffee, McCafe beverages, and other beverages. The company was founded by Raymond Albert Kroc on April 15, 1955, and is headquartered in Oak Brook, IL.

McDonald`s Corp

McDonald's Corp

McDonald's is trending following a strong Q4 earnings beat driven by global comparable sales growth and ambitious plans to expand to 50,000 restaurants by 2027, with the community actively debating if its defensive characteristics and value strategy can sustain momentum amid broader consumer spending concerns and competitor struggles.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU Crypto is trending due to its highly active community consistently building a "permissionless brand" through various real-world product initiatives and events. Community members are actively discussing its long-term potential, encouraging accumulation during market dips, and highlighting its resilience and continuous development in challenging market conditions.

Workday, Inc. engages in the provision of development of enterprise cloud applications for finance and human resources. It delivers financial management, human capital management and analytics applications designed for companies, educational institutions, and government agencies. The company was founded by David A. Duffield and Aneel Bhusri in 2005 and is headquartered in Pleasanton, CA.

Workday Inc - Ordinary Shares - Class A

Workday Inc

Workday is trending amidst an immediate leadership change as its co-founder steps back into the CEO role to steer the company's AI transformation, intensifying community discussion on the software sector's resilience against AI disruption following its latest earnings.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company cooperated wholly with the DOJ’s probe, Cassava said. &nbsp;</li><li>Cassava Sciences is now developing Simufilam to treat tuberous sclerosis complex (TSC)-related epilepsy after dropping its development for Alzheimer’s in early 2025.</li><li>Cassava previously reached a settlement with the SEC regarding the allegations and paid a monetary penalty without admitting or denying the SEC’s allegations.</li></ul>&nbsp;Cassava Sciences, Inc. (SAVA) said on Thursday that the U.S. Department of Justice has closed its probe into the company over allegations of research misconduct pertaining to its drug Simufilam.The company cooperated wholly with the DOJ’s probe, Cassava said. &nbsp;“We welcome the resolution of these investigations and remain dedicated to maintaining the trust of all our stakeholders. As we move forward, we will continue to focus our efforts on developing a novel treatment for TSC-related epilepsy,” &nbsp;CEO Richard J. Barry said.Shares of the company traded 2% lower at the time of writing.<h2 class="st-heading-2">Settlement With SEC</h2>Previously in Sept. 2024, Cassava reached a settlement with the U.S. Securities and Exchange Commission (SEC) regarding the allegations and paid a monetary penalty without admitting or denying the claims. &nbsp;The SEC charged Cassava and two former executives — founder and former CEO Remi Barbier, and former Senior VP of Neuroscience Lindsay Burns — with making misleading statements in 2020 regarding the results of a clinical trial for their experimental Alzheimer's treatment, Simufilam.The regulator alleged that the company claimed the drug "significantly improved patient cognition," while failing to disclose that full patient data showed "no measurable cognitive improvement" in episodic memory.Hoau-Yan Wang, a professor at the City University of New York Medical School, who worked with Cassava to develop the drug, was also charged with manipulating trial data.<h2 class="st-heading-2">Simufilam Now</h2>Cassava Sciences is now developing Simufilam to treat tuberous sclerosis complex (TSC)-related epilepsy after dropping its development for Alzheimer’s in early 2025.The decision to discontinue the Alzheimer’s program followed the drug’s failure to show clinical benefit in a late-stage trial.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around SAVA stock rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume improved from ‘low’ to ‘normal’ levels.A Stocktwits user expressed doubts regarding the allegations raised against the company and said they will not invest in it again.<stembedurl>https://www.stocktwits.com/2bitinvestor/message/645330236</stembedurl><a href="https://stocktwits.com/symbol/SAVA">SAVA stock</a> has dropped 25% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/btm-stock-falls-reverse-split/cZRkTKdR4D4">BTM Stock Pares Early Losses After Company Announces 1-For-7 Reverse Stock Split</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration a Cassava Sciences, Inc. logo is seen on a smartphone screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Cassava Sciences Says DOJ Has Closed Probe Into Allegations Around Its Alzheimer’s Program

The probes into the company by both the DOJ and the SEC have now been closed. 

Equity

Cassava Sciences (NASDAQ:SAVA) Upgraded to Hold at Wall Street Zen

Wall Street Zen raised Cassava Sciences from a "sell" rating to a "hold" rating in a report on Sunday...

HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO...

Cassava Sciences (NASDAQ:SAVA) Stock Price Down 23.9% - What's Next?

Cassava Sciences (NASDAQ:SAVA) Trading Down 23.9% - Here's What Happened...

<ul class="summary-bullets"><li>Cassava said that it intends to work “expeditiously” with the FDA and address the items flagged by the agency.</li><li>The company added that it no longer expects to initiate the trial in question in the first half of 2026.&nbsp;</li><li>Cassava discontinued Simufilam’s study in mild-to-moderate Alzheimer’s disease in March.</li></ul> Shares of Cassava Sciences, Inc.’s slid a deep 24% on Friday after the U.S. Food and Drug Administration placed a full clinical hold on the proposed proof-of-concept clinical trial for Simufilam in tuberous sclerosis complex -related epilepsy.The stock is now on track for its worst day in about 9 months.The company was informed by the FDA of the hold in a letter earlier this week, it said in a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001069530/000143774925038313/sava20251218_8k.htm">filing</a> with the Securities and Exchanges Commission. The company now has to provide the agency with additional information, including additional pre-clinical data, and modify the protocol design.Cassava said that it intends to work “expeditiously” with the FDA and address the items flagged by the agency. The company added that it no longer expects to initiate the trial in question in the first half of 2026.The company failed to provide a new timing for the study, and said it would depend on its ability to provide the requested information and on satisfactory completion of FDA’s review.<h2 class="st-heading-2">Cassava Hits Multiple Roadblocks With Simufilam</h2>Cassava <a href="https://stocktwits.com/news-articles/markets/equity/cassava-sciences-stock-drops-over-30-percent-after-drug-fails-study/ch7yzVjRbdz">discontinued</a> Simufilam’s study in mild-to-moderate Alzheimer’s disease in March after the drug did not fare better than placebo in reducing cognitive or functional decline in a late-stage study. The company discontinued its efforts to develop the drug for Alzheimer’s disease and phased out the program and then committed to evaluating the drug’s potential in TSC-related epilepsy.Tuberous Sclerosis Complex (TSC) is a rare genetic disorder causing non-cancerous tumors (hamartomas) to grow in many organs, primarily the brain, skin, kidneys, heart, lungs, and eyes. It can lead to symptoms including seizures, developmental delays, intellectual disabilities, and skin abnormalities.According to Austin-based Cassava, TSC affects nearly 50,000 people in the US and epilepsy is one of the most common neurological features of TSC, occurring in 84% of patients. Current therapies for the condition include antiepileptic drugs and mTOR inhibitors which are not fully effective, and are associated with serious adverse events, the company said in November.Cassava decided to study Simufilam in TSC-related epilepsy on the results of two sophisticated studies conducted in animals that support the drug’s potential, CEO Rick Barry said last month. &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around SAVA fell from ‘bearish’ to ‘extremely bearish' territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.A Stocktwits user highlighted a buying opportunity.<stembedurl>https://www.stocktwits.com/MrStockxy/message/639701864</stembedurl><a href="https://stocktwits.com/symbol/SAVA">SAVA stock</a> has dropped 8% this year and by 5% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/rocket-lab-stock-heads-for-its-best-day-in-over-8-months-rally-isn-t-only-about-trump/cLe0GDaREst">Rocket Lab Stock Heads For Its Best Day In Over 8 Months — And The Rally Isn’t Only About Trump</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Cassava Sciences Stock On Track For Worst Day In About 9 Months — What’s Driving Today’s Selloff?

FDA placed a clinical hold on the proposed proof-of-concept clinical trial for Simufilam in tuberous sclerosis complex -related epilepsy earlier this week.

FDA Puts Cassava's Simufilam Epilepsy Trial On Full Clinical Hold

Cassava Sciences confirms an FDA clinical hold on its simufilam epilepsy trial, delaying plans and requiring more data despite strong cash reserves.read more...

Cassava Sciences (NASDAQ:SAVA) CEO Purchases $201,808.75 in Stock

Cassava Sciences, Inc. (NASDAQ:SAVA - Get Free Report) CEO Richard Barry bought 73,385 shares of the business's stock in a transaction that occurred on Wednesday, November 19th. The stock was bought...

Cassava Sciences Sees Unusually High Options Volume (NASDAQ:SAVA)

Cassava Sciences, Inc. (NASDAQ:SAVA - Get Free Report) was the recipient of some unusual options trading activity on Thursday. Traders purchased 8,896 call options on the company. This represents an...

Insider Buying: Cassava Sciences (NASDAQ:SAVA) CEO Acquires 73,385 Shares of Stock

Cassava Sciences, Inc. (NASDAQ:SAVA - Get Free Report) CEO Richard Barry bought 73,385 shares of the business's stock in a transaction on Wednesday, November 19th. The stock was bought at an average...

Cassava Sciences (NASDAQ:SAVA) Trading Down 3% - What's Next?

Cassava Sciences (NASDAQ:SAVA) Shares Down 3% - Time to Sell...

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

SAVA
Cassava Sciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SAVA News

SAVACassava Sciences Inc